Literature DB >> 11396151

Increased expression of peroxiredoxin II confers resistance to cisplatin.

Y M Chung1, Y D Yoo, J K Park, Y T Kim, H J Kim.   

Abstract

Peroxiredoxin II (Prx II) has been known to be induced by various oxidative stimuli and to play an important protective role from oxidative damage by hydrogen peroxide (H2O2). In this study, we observed that cisplatin as well as H2O2 induced Prx II expression. To examine the correlation between the increased expression of Prx II and chemoresistance, we prepared a Prx II-overexpressing cell line, SNU638 cells, and found it to be more resistant to cell death induced by cisplatin and H2O2 than neo-transfectant cells. We also observed that enhanced expression of Prx II inhibited cisplatin- and H2O2-induced apoptosis, demonstrating that resistance to these cytotoxic agents was due to inhibition of apoptosis. The above results led us to suggest that the overexpressed Prx II protein inhibits cisplatin-induced apoptosis, thereby contributing to chemoresistance of tumor cells, especially to oxidative stress producing anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11396151

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  30 in total

Review 1.  Mitochondrial thiols in the regulation of cell death pathways.

Authors:  Fei Yin; Harsh Sancheti; Enrique Cadenas
Journal:  Antioxid Redox Signal       Date:  2012-06-11       Impact factor: 8.401

2.  Peroxiredoxin II regulates effector and secondary memory CD8+ T cell responses.

Authors:  Ryan D Michalek; Katie E Crump; Ashley E Weant; Elizabeth M Hiltbold; Daniel G Juneau; Eun-Yi Moon; Dae-Yeul Yu; Leslie B Poole; Jason M Grayson
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

3.  Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade.

Authors:  Xiaoming Hu; Zhongfang Weng; Charleen T Chu; Lili Zhang; Guodong Cao; Yanqin Gao; Armando Signore; Jianhui Zhu; Teresa Hastings; J Timothy Greenamyre; Jun Chen
Journal:  J Neurosci       Date:  2011-01-05       Impact factor: 6.167

Review 4.  The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.

Authors:  Paul A Marks
Journal:  Expert Opin Investig Drugs       Date:  2010-09       Impact factor: 6.206

5.  Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.

Authors:  Lixu Jin; Yi Huo; Zhiguo Zheng; Xiaoyong Jiang; Haiyun Deng; Yuling Chen; Qingquan Lian; Renshan Ge; Haiteng Deng
Journal:  Mol Cell Proteomics       Date:  2014-08-05       Impact factor: 5.911

6.  Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors.

Authors:  Sally Järvelä; Immo Rantala; Alejandra Rodriguez; Heini Kallio; Seppo Parkkila; Vuokko L Kinnula; Ylermi Soini; Hannu Haapasalo
Journal:  BMC Cancer       Date:  2010-03-22       Impact factor: 4.430

Review 7.  Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment.

Authors:  Jian-Ting Zhang; Yang Liu
Journal:  Cancer Treat Rev       Date:  2007-09-12       Impact factor: 12.111

8.  Cloning and expression of mouse peroxiredoxin I in IEC-6 Cells.

Authors:  Bo Zhang; Yong-Ping Su; Tao Wang; Feng-Chao Wang; Guo-Ping Ai; Hui Xu; Jun-Ping Wang; Yue-Sheng Huang; Jian-Xin Jiang
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

Review 9.  Peroxiredoxins, gerontogenes linking aging to genome instability and cancer.

Authors:  Thomas Nyström; Junsheng Yang; Mikael Molin
Journal:  Genes Dev       Date:  2012-09-15       Impact factor: 11.361

10.  Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.

Authors:  Jianli Chen; Mahesha Adikari; Rajash Pallai; Hemant K Parekh; Henry Simpkins
Journal:  Cancer Chemother Pharmacol       Date:  2007-07-28       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.